Innovent and Lilly win second China OK for Tyvyt in frontline NSCLC, ramping up pressure on king Keytruda
Innovent Biologics and its partners at Eli Lilly have notched another arrow in their quiver in their bid to take down Merck’s Keytruda.
Chinese regulators granted a prominent new approval for the pair’s Tyvyt on Wednesday, indicating the drug for first-line treatment of nonsquamous non-small cell lung cancer in combination with pemetrexed and platinum chemo. It’s the second approval in the country for the Chinese powerhouse and American Big Pharma, after Tyvyt was OK’ed in 2018 for relapsed or refractory classical Hodgkin’s lymphoma after two lines of chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.